Company news

MaaT Pharma news in 2025

MaaT Pharma's news releases, calls and decks from 2025, newest first.

View company

MaaT Pharma Presents Pivotal ARES Phase 3 Results for MaaT013 (Xervyteg®) in Acute GvHD at ASH 2025 Annual Congress and Announces 54% 1-Year Overall Survival

December 8, 2025

MaaT Pharma Announces the Successful Completion of Its Global Offering of €9.1 Million

November 14, 2025

MaaT Pharma Launches a Capital Increase of Approximately €9 Million

November 13, 2025

MaaT Pharma Presents Updated Preclinical Data at SITC Annual Meeting Demonstrating Immune Activation and Anti-Tumor Activity of MaaT034

November 5, 2025

MaaT Pharma Reports Financial Results for the Third Quarter 2025 and Provides Financing Update

November 4, 2025

MaaT Pharma Announces Positive Phase 3 Results Evaluating Xervyteg® (MaaT013) in Acute Graft-versus-Host Disease Selected for Oral Presentation at ASH Congress 2025

November 3, 2025

MaaT Pharma Announces Positive Second Safety Interim Analysis from DSMB for Phase 2b PHOEBUS Trial Evaluating MaaT033 for Patients Receiving Allo-HSCT

October 7, 2025

MaaT Pharma Publishes Its Half Year 2025 Results and Provides a Business Update

September 17, 2025

MaaT Pharma Secures €37.5 Million Loan From European Investment Bank (EIB) Marking a New Step in Advancing its Clinical Program in Hemato-Oncology

July 28, 2025

MaaT Pharma: Half-year Report to the Liquidity Contract With Kepler Cheuvreux

July 24, 2025

MaaT Pharma Announces Exclusive Commercialization Partnership With Clinigen for Xervyteg(R) in acute Graft-versus Host Disease in Europe

July 3, 2025

MaaT Pharma Announces Exclusive Commercialization Partnership With Clinigen for Xervyteg® in acute Graft-versus Host Disease in Europe

July 2, 2025

MaaT Pharma Presents the Results of its Annual Ordinary and Extraordinary General Meeting

June 24, 2025

MaaT Pharma Provides a Business Update and Highlights Key Milestones Expected in 2025

June 19, 2025

MaaT Pharma Presents Updated Positive Data in Early Access Program for Xervyteg® at the EHA Congress Validating High Efficacy Observed in Pivotal ARES Study in Acute Graft-versus-Host Disease

June 13, 2025

MaaT Pharma Advances Toward Commercialization And Submits Marketing Authorization Application to the European Medicines Agency (EMA) for Xervyteg® (MaaT013) in Acute Graft-versus-Host Disease

June 2, 2025

MaaT Pharma to Hold Annual General Meeting on June 20, 2025

May 14, 2025

MaaT Pharma Provides Business Update and Reports Financial Results for the First Quarter 2025

May 13, 2025

MaaT Pharma Announces Promising Final Data Readout for Phase 1b Evaluating MaaT033 in Amyotrophic Lateral Sclerosis (ALS)

May 12, 2025

Decks in 2025